Luxembourg Institute of Health

Efficacy of VAL-083 in primary and recurrent brain tumor biopsies. VAL-083 showed consistent and superior anti-tumor activity against MGMT-unmethylated tumors in comparison to temozolomide

AACR Annual Meeting 2019

Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor growth upon bevacizumab-induced hypoxia, in vivo

AACR Annual Meeting 2019

Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting

AACR Annual Meeting 2019

Phase 2 study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma

AACR Annual Meeting 2019

Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of diffuse intrinsic pontine glioma (DIPG)

Society for NeuroOncology

Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve recurrent glioblastoma